Table 3.

Comparison of HDDT effectiveness by previous antibiotic prescriptions.

	ITT n/N (%)		p	PP n/N (%)		p	mITT n/N (%)		p
	Not Previously Used	Previously Used		Not Previously Used	Previously Used		Not Previously Used	Previously Used
A	11/20 (55%)	17/40 (42.5%)	0.360	11/17 (64.7%)	17/37 (45.9%)	0.200	11/17 (64.7%)	17/38 (45.9%)	0.171
C	12/22 (54.5%)	16/38 (42.1%)	0.352	12/19 (63.2%)	16/35 (45.7%)	0.221	12/19 (63.7%)	16/36 (44.4%)	0.187
M-T	19/30 (63.3%)	9/30 (30.1%)	0.010	19/27 (70.4%)	9/27 (33.3%)	0.006	19/27 (70.4%)	9/28 (32.1%)	0.005
L-Mx	13/25 (52%)	15/35 (42.9%	0.484	13/22 (59.1%)	15/32 (46.9%)	0.377	13/22 (59.1%)	15/33 (45.5%)	0.322
B	15/29 (51.7%)	13/31 (41.9%)	0.448	15/24 (60%)	13/29 (44.8%)	0.266	15/25 (60%)	13/30 (43.3%)	0.218
Tc-Dc	22/36 (61.1%)	6/24 (25%)	0.006	22/32 (68.8%)	6/22 (27.3%)	0.003	22/32 (68.8%)	6/23 (26.1%)	0.002
Rf	23/40 (57.5%)	5/20 (25%)	0.017	23/35 (65.7%)	5/19 (22.7%)	0.006	23/35(65.7%)	5/20 (25%)	0.004

A, amoxicillin; B, bismuth salts; C, clarithromycin; Conc, concomitant; HDDT, high-dose dual therapy; Hyb, hybrid; ITT, intention to treat; L-Mx, levofloxacin or moxifloxacin; M-T, metronidazole or tinidazole; mITT, modified intention-to-treat; PP, per protocol; PPI, proton pump inhibitor; Rf, rifabutin; Seq, sequential; Tc-Dc, tetracycline or doxycycline. HDDT eradication rates in patients previously treated with different antibiotics. The Chi-square test was used at a significance level of p < 0.005.